INTRODUCTION

The number of testosterone prescriptions written in the United States in the first decade of this century has progressively increased, with most of the prescriptions dispensed to middle-aged and older men. In 2011, approximately 3% of men over the age of 40 years received at least one prescription; and recent data suggest that this increase in dispensing is a global trend. Considering that (i) there has not been a population-level increase in the incidence of pathological (“classical”) androgen deficiency (as a result of congenital or acquired hypothalamic, pituitary, or testicular disease), (ii) no new formal indications for testosterone therapy have emerged, and (iii) guidelines for male androgen deficiency have not changed, the increase in prescription rate is mainly driven by clinicians who prescribe testosterone to treat age-related low serum testosterone levels in middle-aged or older men (many who present with nonspecific symptoms) and is a result of a sophisticated marketing campaign by the industry. Interestingly (and unfortunately), one in six men who are prescribed testosterone therapy do not have a baseline serum testosterone measured, suggesting that practice patterns do not conform to published guidelines.

There is general consensus that testosterone replacement is beneficial in young androgen-deficient men with an organic etiology for their androgen deficiency; these benefits include increased muscle mass and strength, increased bone mineral density, improvement in sexual function, and energy. Additionally, physiological testosterone replacement in young men is associated with a low frequency of side effects that include acne, oily skin, transient breast tenderness or gynecomastia, and erythrocytosis; these side effects are dose-dependent and are more common with short-acting intramuscular injections. In contrast, in older men with age-related low testosterone, benefits of testosterone replacement are at best, modest. Although some recent large trials of testosterone therapy in older men have demonstrated modest improvements in sexual function, mood, bone density (although anti-fracture efficacy is unknown), and anemia (per se not an indication for testosterone therapy), no improvement was seen in cognitive function while effects on physical function have been inconsistent. Although benefits of testosterone therapy in older men are modest, its potential effect on prostate safety remains unknown. Furthermore, some recent trials have reported an increased incidence of cardiovascular adverse events in men on testosterone therapy, mainly involving older men and those with prevalent cardiovascular disease. Although none of these trials were adequately powered to assess cardiovascular events, these studies have raised questions regarding the cardiovascular safety of testosterone therapy in this patient population.

In this review, we discuss (i) clinical trials of testosterone therapy that have reported cardiovascular events, (ii) relevant trials that did not show an increased risk, and (iii) large trials that have evaluated atherosclerosis progression as the primary outcome. We summarize meta-analyses of testosterone trials that have evaluated cardiovascular events. Finally, we discuss some potential mechanisms by which testosterone use might result in an increased cardiovascular risk. As none of the trials conducted to date were adequately powered to evaluate cardiovascular events, no firm conclusions can be drawn regarding the cardiovascular safety of testosterone therapy at this time. In the interim, we hope that this review will help practitioners make informed decisions regarding the care of their patients.
mechanisms that might be involved in cardiovascular events reported in some studies.

SMALL MECHANISTIC STUDIES SHOWING POTENTIAL CARDIOVASCULAR BENEFIT OF TESTOSTERONE THERAPY

In a few small mechanistic studies, testosterone therapy has shown benefits in some select cardiovascular parameters. In a placebo-controlled study of 50 men with ST-segment depression on exercise testing at baseline, treatment with intramuscular testosterone cypionate at 200 mg per week for 8 weeks showed a 51% reduction in the sum of ST segment depression at the end of treatment.32 In another 12-week trial of 5 mg transdermal testosterone patch in 22 men with stable angina, the time to 1 mm ST-segment depression on the treadmill exercise test improved with testosterone.33 Beneficial effects of testosterone on myocardial ischemia were also reported in a small 12-month study of 15 men; 7 of whom received intramuscular testosterone undecanoate.34 The results of these trials seem to suggest that testosterone has beneficial effects on the coronary vasculature; this was verified in another small study of 13 men with angiographically proven coronary artery disease showing coronary vasodilation in response to intracoronary administration of testosterone.35

Limited data, mainly from small trials, also suggest beneficial effect of testosterone on aerobic function. A trial of 76 men with congestive heart failure given transdermal testosterone patch for 12 months improved their performance on the incremental shuttle walk test.36 However, only a quarter of these men had low testosterone levels at baseline and only 42 men completed the 12-month intervention. Another 12-week trial of long-acting intramuscular testosterone preparation in older men with chronic heart failure improved aerobic capacity, baroreflex sensitivity, and 6-min walking distance.37 Similarly, in a subset analysis of 64 mobility-limited older participants in the Testosterone in Older Men with Mobility Limitation (TOM) Trial, daily application of testosterone gel for 6 months attenuated the age-related decline in aerobic function.38

Together, these mechanistic studies suggest that testosterone therapy might be beneficial to the cardiovascular system; however, the findings from these studies should be interpreted with caution as – (i) these trials enrolled a small number of men, (ii) all enrolled subjects did not have low serum testosterone levels, and (iii) some studies used routes of testosterone administration that cannot be replicated in clinical practice (e.g., intra-coronary infusion).

CARDIOVASCULAR EVENTS IN CLINICAL TRIALS OF TESTOSTERONE REPLACEMENT

In this section, we discuss trials that have reported higher incidence of cardiovascular events in men treated with testosterone, relevant trials of testosterone therapy that have not reported increased cardiovascular events, and relatively large clinical trials that assessed atherosclerosis progression as their primary outcome.

The copenhagen study group: testosterone in alcoholic cirrhosis trial

One of the first trials that reported a higher mortality with testosterone treatment evaluated the effects of 600 mg of micronized testosterone compared with placebo on survival in 221 men with alcoholic cirrhosis.29 Participants were followed for a median of 28 months. The trial was stopped prematurely as the mortality data revealed an increased death rate in the testosterone group (17% higher than placebo); the majority of the deaths were apparently related to hepatic complications. This trial was neither designed to evaluate cardiovascular risk nor did it demonstrate increased cardiovascular event rate (only one confirmed myocardial infarction); however, it deserves mention as it is frequently cited and included in meta-analyses reviewing cardiovascular safety of testosterone therapy.

Clinical trial in men 65 years and older

In a 36-month trial of transdermal testosterone replacement in men aged 65 years and older,40,41 a higher number of cardiovascular events were seen in the testosterone arm (9 vs 5 in placebo group), although this difference was not statistically significant.42 Interestingly, 3 of the events in men receiving testosterone were arrhythmias. A secondary analysis of this trial showed that testosterone therapy did not significantly influence any of the lipoprotein parameters.42 Although the total number of events in this trial was small, this trial is also frequently included in meta-analyses.

Clinical trial in men with anemia of chronic renal disease

This frequently-cited trial evaluated whether treatment with transdermal testosterone gel reduces the requirement for recombinant human erythropoietin in forty men on hemodialysis who had low serum testosterone and anemia of renal failure.43 A slightly higher number of cardiovascular events occurred in the testosterone group compared with placebo (7 vs 3); details regarding these events were not reported. This trial was also not designed to evaluate cardiovascular events.

TOM trial

The TOM trial was published in 2010 and reported an increased incidence of cardiovascular-related events in older men receiving testosterone therapy.29 The trial enrolled men 65 years of age or older with limitations in mobility (based on subjective and objective criteria) and serum total testosterone <350 ng dl⁻¹ or free testosterone <50 pg ml⁻¹ who either received 100 mg of transdermal testosterone gel or placebo gel for 6 months. The original goal of the trial was to randomize 252 men; however, the trial was stopped prematurely (after 209 randomizations) by the trial’s Data and Safety Monitoring Board because of higher incidence of cardiovascular-related events in the testosterone arm (23 vs 5 in the placebo arm). The cardiovascular-related events seen were diverse and included both atherosclerotic and nonatherosclerotic events; major adverse cardiovascular events were only seen in the testosterone group.29 Interestingly, the difference in the frequency of cardiovascular events between the two groups was apparent within weeks of randomization, suggesting an acute mechanism behind these events (Figure 1). In the testosterone arm, men who experienced cardiovascular-related events had higher on-treatment circulating serum total testosterone concentrations compared with men who did not;29 however, secondary analyses showed that only changes in serum free testosterone levels were associated with events.44

A few aspects of the TOM Trial should be highlighted. First, the participants in the TOM Trial had a high prevalence of cardiovascular
risk factors at baseline; not an unexpected observation as the burden of comorbidities is high in mobility-limited men. Indeed, nearly 25% of the participants had diabetes mellitus, half were obese, >80% had hypertension and approximately 50% of the participants had preexisting heart disease. Second, the starting dose of testosterone gel in the TOM Trial was higher than the dose at which treatment is initiated in clinical practice. However, the on-treatment circulating mean serum testosterone levels in the TOM Trial were comparable to the levels seen in older men who participated in other trials; however, the majority of other studies enrolled “healthy” older men. Finally, the diversity of cardiovascular-related events seen in the TOM Trial does not suggest a single mechanism; though the rapidity with which the events occurred suggests an acute mechanism. Indeed, this early increase in cardiovascular risk was also reported in a large population study that showed a 2-fold increase in the risk of cardiovascular events within the first 90 days following the initiation of testosterone therapy. In contrast, early cardio renal events have not been reported in other epidemiologic studies or in the Testosterone Trials (TTrials).

Clinical trial in intermediate-frail and frail men
In an elegant clinical trial from Manchester, United Kingdom, 274 intermediate-frail and frail men (based on the Fried criteria) aged 65 years and older with serum testosterone concentration less than 345 ng dL⁻¹ were randomized to topical testosterone gel or placebo for 6 months; the starting daily dose was 50 mg. This trial did not find a higher incidence of cardiovascular events in the testosterone group (one case each of myocardial infarction and ruptured aneurysm [death] in the placebo group while one case each of constrictive pericarditis [death], angina, pulmonary embolism, and abdominal aneurysm surgery in the testosterone arm). This trial is frequently cited along with the TOM Trial, mainly to contrast the cardiovascular findings between the two trials; however, unlike the TOM Trial (in which all participants were mobility-limited), only 15% of men in this trial met the criteria of frailty while the remaining men were intermediate-frail. Consideration of this characteristic of this trial’s population is important as frailty is associated with a greater burden of subclinical cardiovascular disease compared to subjects who are prefrail. In addition, in contrast to the TOM Trial, the average baseline serum testosterone concentrations in men participating in this trial were in the low-normal range; therefore, the findings of this trial cannot be extrapolated to men with unequivocally low serum testosterone levels.

The Testosterone’s Effect on Atherosclerosis Progression in Aging Men (TEAAM) Trial
The Testosterone’s Effects on Atherosclerosis Progression in Aging Men (TEAAM) trial was designed to evaluate the effect of testosterone therapy in 308 men, 60 years and older, with low or low-normal total testosterone (100–400 ng dL⁻¹) or free testosterone <50 pg ml⁻¹ on progression of subclinical atherosclerosis in the common carotid artery (assessed by sonographic measurement of common carotid intima-media thickness) and the coronary arteries (assessed by measurement of coronary artery calcium score with computerized tomography scan). Men received either 7.5 g of 1% transdermal testosterone gel or placebo gel daily for 3 years. Overall, there were small number of cardiovascular adverse events in the trial, and the major adverse cardiac events did not differ between the two groups: three men in the testosterone versus two in the placebo arm had myocardial infarction, five men in the testosterone versus two in the placebo arm underwent coronary revascularization, three men in the testosterone versus zero in the placebo arm experienced a stroke, and one man in the testosterone versus zero in the placebo group died of a cardiovascular-related event. No significant difference in the rate of change in either common carotid artery intima-media thickness or coronary artery calcium scores was observed between the groups (Figure 2). These findings suggest that testosterone treatment is not associated with progression of carotid intima-media thickness or progression of calcified coronary plaques; noncalcified coronary plaques were not measured in this trial. Of note, the mean baseline serum testosterone concentrations in men participating in the TEAAM trial was in the low-normal range; therefore, these findings cannot be extrapolated to men with low serum testosterone levels.

Considering that some studies have shown that cardiovascular adverse events occur early after initiation of testosterone treatment, the TEAAM trial investigators also evaluated the effect of testosterone treatment on electrocardiographic parameters, mainly ventricular repolarization, as assessed by the corrected QT interval (QTc). As prolongation of the QT interval is a risk factor for ventricular arrhythmias and sudden death, the TEAAM trial provided an opportunity to assess the long-term effect of testosterone treatment on cardiac conduction system. In addition to the TEAAM trial, the same investigators also evaluated the effect of testosterone therapy on QTc in the Testosterone and Pain (TAP) trial, a 14-week trial assessing the efficacy of testosterone replacement on pain perception in men with opioid-induced androgen deficiency. The investigators found that testosterone treatment did not prolong QTc duration in either trial. Furthermore, testosterone therapy was associated with attenuation of the expected age-related increase in QTc duration in the TEAAM trial. These findings suggest that testosterone administration is not associated with arrhythmogenic changes, making it an unlikely mechanism behind acute cardiovascular events.

The TTrials
The TTrials were a group of seven coordinated multicenter, double-blind, placebo-controlled trials evaluating the efficacy of testosterone replacement in 790 men, 65 years or older, with an average of two total testosterone values <275 ng dL⁻¹. Men were randomized to daily application of topical testosterone gel or placebo gel for 1 year. At the end of the intervention phase of the trial, there was no difference in the number of cardiovascular events between the two groups; seven men in each group experienced a major adverse cardiovascular event (myocardial infarction, stroke or death related to cardiovascular disease).
One of the seven coordinated trials of the TTrials was the Cardiovascular Trial, which evaluated the effect of testosterone treatment on the progression of both calcified and noncalcified coronary artery plaque volume using computerized tomography angiography scan in a subset of 138 participants. After 12 months of intervention, testosterone treatment was associated with a greater increase in the volume of noncalcified plaque compared with placebo (Figure 3); there was no significant difference in the change in calcified plaque between the groups. Although definitive evidence regarding cardiovascular safety of testosterone therapy will only emerge from large, adequately powered trials that are designed to assess cardiovascular event rate, based on these findings of greater progression in noncalcified plaque, one might speculate that the rupture (and thrombosis) of the soft plaque might explain some of the cardiovascular events that occur early after initiation of testosterone therapy.

In summary, the number of cardiovascular events reported in TTrials are low; in fact, it is lower than the expected rate for the age and comorbidities of the participants. None of the trials discussed above was powered to evaluate cardiovascular events and most enrolled a small number of participants, making any small differences between groups inconclusive. Furthermore, the recording and reporting of adverse events in previous testosterone trials have not followed a standardized format, underscoring the need for standardization of adverse event reporting in future trials.META-ANALYSES OF RANDOMIZED TTrials REPORTING CARDIOVASCULAR EVENTS

Several meta-analyses have attempted to elucidate the association between testosterone administration and cardiovascular events; however, it is difficult to draw firm conclusions as these analyses have pooled trials that were of low-to-medium quality, enrolled men with variable characteristics, used different testosterone doses and formulations, duration of treatment was not uniform, and none of these trials were powered to evaluate cardiovascular events. As a result, some meta-analyses of placebo-controlled trials have not found an association between testosterone therapy and cardiovascular events, whereas others have found such an association (Figure 4).

Meta-analyses showing neutral effects of testosterone therapy

In 2005, a meta-analysis of 19 randomized controlled trials of men 45 years or older with low or low-normal testosterone who were treated with testosterone (n = 651) or placebo (n = 433) for at least 90 days was published. The pooled analyses showed 18 cardiovascular events in the testosterone arm (including four myocardial infarctions and three strokes), whereas 16 events were observed in the placebo group (including three myocardial infarctions and four strokes); the difference in event rate with testosterone treatment was not significantly different (pooled odds ratio [OR] for all cardiovascular events 1.14, 95% confidence interval [CI]: 0.59 – 2.20). Although these findings seem to be reassuring, this meta-analysis included relatively young men. Another study reviewed thirty clinical trials comprising a total pool of 1642 men; however, the authors concluded that most of these trials were not methodologically sound and short-listed only six clinical trials (that reported allocation concealment) for their meta-analysis. In these six trials, 14 cardiovascular events occurred in 161 men who received testosterone while seven events occurred among the 147 men who were assigned to placebo, resulting in a pooled OR of 1.82 (95%CI: 0.78 – 4.23), which was statistically nonsignificant. The OR for fatal and nonfatal myocardial infarction was 2.24 (95%CI: 0.5 – 10.02). The authors concluded that their data weakly supports the notion that use of testosterone in men is not associated with clinically important cardiovascular events. Another systematic review and meta-analysis of 51 randomized and nonrandomized trials that included 2679 men showed no significant effect of testosterone therapy on mortality or any cardiovascular outcome (including arrhythmias, coronary bypass surgery, and myocardial infarction). However, these studies were considered low to medium quality, and of the 51 studies included, only nine reported cardiovascular outcomes. A recent meta-analysis of 75 randomized controlled trials also did not find an association between testosterone treatment and cardiovascular events.

Meta-analyses showing harmful effects of testosterone therapy

In a meta-analysis by Xu et al, 27 27 trials were selected, yielding a sample of 2994 men who experienced 180 cardiovascular-related events. In this study, testosterone therapy was associated with an increased risk of a cardiovascular-related event (OR: 1.54; 95%CI: 1.09 – 2.18). Interestingly, this risk was higher in trials that were not funded by the pharmaceutical industry (OR: 2.06; 95%CI: 1.34 – 3.17 vs OR: 0.89; 95%CI: 0.50 – 1.60 for industry-funded studies). Possible explanations for this discrepancy include: (i) difference in age of the participants as industry-funded trials generally enrolled younger men, and (ii) trials conducted in an academic setting usually enroll subjects with a higher degree of morbidity, as the main objective of such trials is to improve health outcomes (such as mobility-limitation, sexual dysfunction, and depression); to the contrary, the primary objective of many industry-funded trials is to evaluate the efficacy of their product in increasing serum testosterone levels, which can be achieved by enrolling hypogonadal men who are generally healthy. Another recent systematic review and meta-analysis evaluated the risk of testosterone therapy on cardiovascular events in 5328 men who were pooled from 45 clinical trials. Overall, testosterone treatment was not associated with an increased cardiovascular
event risk ratio (RR 1.10; 95%CI: 0.86–1.41; P = 0.45). However, in men age 65 years or older, there was a significant increase in cardiovascular event rate (RR: 2.90; 95%CI: 1.35–6.21; P = 0.006) which was evident mainly in the first 12 months of therapy. Oral (RR: 2.28; 95%CI: 2.28–8.59; P = 0.22) and transdermal testosterone therapy were associated with higher cardiovascular event rate (RR: 2.80; 95%CI: 1.38–5.68; P = 0.004) compared with intramuscular testosterone administration (RR: 0.96; 95%CI: 0.46–1.98; P = 0.91).

In summary, these meta-analyses provide limited information, as they are limited by the fact that most studies included were low-to-medium quality and none was powered to evaluate cardiovascular events. Therefore, firm conclusions regarding the cardiovascular safety of testosterone therapy cannot be drawn from these data.

**POTENTIAL MECHANISMS INVOLVED IN CARDIOVASCULAR EVENTS**

As cardiovascular events seen in some testosterone trials have been diverse, it is difficult to implicate a single mechanism. Preclinical data from mechanistic animal studies show both beneficial and detrimental effects of testosterone administration. For instance, animal studies have shown that androgens promote sodium reabsorption in the kidneys by up-regulating the renin-angiotensin system, which leads to expansion in extracellular volume which in turn, could lead to hypertension.60–61 To the contrary, testosterone stimulates nitric oxide (NO) production by the endothelial cells *in vitro*62–63; indeed, NO-mediated vasodilation of coronary and other systemic arteries in response to testosterone administration has been shown in several animal models.64–67 Similarly, animal studies show that testosterone administration stimulates proliferation and migration of vascular smooth muscle cells in culture through both genomic and nongenomic mechanisms,68 but in androgen-deficient animal models of atherosclerosis, testosterone administration protects against plaque formation.69–72

Similar to animal studies, data from human studies are also conflicting (as discussed earlier). However, based on the types of adverse events seen in clinical trials, we discuss some potential mechanisms that might be involved in triggering these events.

**Hypercoagulability and thrombosis**

Some studies have suggested that testosterone administration induces platelet aggregability by increasing thromboxane A2 receptor density on human platelets,73 which is reversed by castration.74 A recent population-based case-control study reported that testosterone treatment was associated with increased risk of venous thromboembolism within the first 6 months of treatment regardless of the underlying risk factors,75 though some other population studies have not shown this association. In addition to the independent effect of testosterone on platelet aggregation, estradiol (an active metabolite of testosterone) also has direct effects on platelet aggregability and thrombosis. In the TOM Trial, men who were randomized to testosterone and experienced cardiovascular events had higher on-treatment circulating mean serum total testosterone, free testosterone, estradiol, and estrone levels compared with men in the testosterone arm who did not have an event (Figure 5).76 Though in a different context than testosterone replacement, the Coronary Drug Project and studies of men with prostate cancer, in which participants were treated with exogenous estrogens, also observed a higher incidence of myocardial infarction, stroke, and pulmonary embolism.76–78 Hence, it is conceivable that early events seen in some testosterone trials might be related to thrombosis.

**Plaque destabilization and rupture**

Another potential mechanism behind acute cardiovascular events might be plaque destabilization. Erythrocytosis resulting from testosterone administration increases blood viscosity, which is a key parameter responsible for shear stress action on the endothelial wall,79 and a trigger for plaque rupture.80–82 Because noncalcified plaques in the coronary artery are considered unstable (and are most vulnerable to rupture), and as recent evidence from the TTrial showed the greater progression of noncalcified coronary plaques in the testosterone group,83 it is conceivable that some early events associated with testosterone treatment might be due to plaque erosion and thrombosis.

**Fluid retention**

Another mechanism by which testosterone might contribute to cardiovascular events is by salt and water retention. It has been known for some time that testosterone increases renal sodium reabsorption, which results in an expansion of extracellular volume84 and an increase in blood pressure.84 In healthy men, pressure natriuresis leads to excretion of this excess water, however, men with underlying cardiac or renal abnormalities may not be able to efficiently excrete excess water, which could result in fluid overload. Indeed, exacerbation of congestive...
heart failure has been reported in some trials of testosterone therapy in older men with underlying comorbidities.\textsuperscript{29,44} 

**CONCLUSIONS**

To date, not a single published trial of testosterone treatment was adequately powered to assess cardiovascular events. Only a large, well-designed, adequately-powered, and randomized placebo-controlled trial will definitively answer the question regarding cardiovascular safety of testosterone therapy. Until such a trial is conducted, and the results become available, the clinicians should have an open discussion with their patients regarding the available evidence of cardiovascular safety of testosterone therapy. This discussion will not only allow the clinicians to counsel men regarding their likelihood to benefit from testosterone therapy and to discuss their risk/benefit ratio, but will also help the patients in making informed decisions. In the interim, the investigators should conduct mechanistic studies to understand the effects of testosterone on coagulation parameters, platelet function, plaque stability and water metabolism. Based on the current evidence, no firm conclusions can be drawn regarding the cardiovascular safety of testosterone therapy.

**AUTHOR CONTRIBUTIONS**

TGJ and SB conceptualized this work together and also contributed equally to the drafting of the manuscript. Both authors read and approved the final manuscript.

**COMPETING INTERESTS**

Dr. Basaria has previously served as a consultant to AbbVie Pharmaceuticals. Dr. Gaglione-Jucá has no competing interests.

**ACKNOWLEDGMENTS**

Dr. Gaglione-Jucá and Dr. Basaria would like to thank the staff of the Section on Men's Health and also the subjects who participated in their clinical trials.

**REFERENCES**


This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

©The Author(s)(2017)